Overview of the Clinical Features of Li-Fraumeni Syndrome and the Current European ERN GENTURIS Guideline

Abstract

Patients with a tumour-risk syndrome have a significantly increased risk of developing cancer during their lifetime. A positive family history of tumour disease or an unusually early age of onset may be indicative of a tumour risk syndrome. With the diagnosis of a tumour risk syndrome it is possible to recommend a risk-adapted tumour surveillance programme for the patient and (asymptomatic) family members at risk. This facilitates early detection of possible tumours and thus often prevents advanced tumour stages. Li-Fraumeni syndrome is associated with a significantly increased risk of sarcoma and breast cancer in particular, but it is often not diagnosed clinically in those affected. This article reviews the clinical picture, genetic cause and special aspects in the diagnosis and care of patients with Li-Fraumeni syndrome. The initiative resulted from the European reference network GENTURIS, which has set itself the task of improving the identification and care of patients with tumour risk syndromes. A first step is the recent publication of a European guideline for Li-Fraumeni syndrome, which is summarised here and discussed in the context of existing recommendations.

Key words

Li-Fraumeni syndrome - TP53 - tumour risk syndromes - cancer screening - guideline

Publikationsverlauf

Eingereicht: 17. März 2021

Angenommen nach Revision: 29. Juni 2021

Artikel online veröffentlicht:
25. Oktober 2021

• References/Literatur

• 1 Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.. Krebs in Deutschland 2015/2016. Robert Koch-Institut: 2019
• 2 Mai PL, Best AF, Peters JA. et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 2016; 122: 3673-3681 DOI: 10.1002/cncr.30248.
• 3 Guha T, Malkin D. Mutations and the Li–Fraumeni Syndrome. Cold Spring Harb Perspect Med 2017; DOI: 10.1101/cshperspect.a026187.
• 4 Bourdon J-C, Fernandes K, Murray-Zmijewski F. et al. p 53 isoforms can regulate p 53 transcriptional activity. Genes Dev 2005; 19: 2122-2137 DOI: 10.1101/gad.1339905.
• 5 Marcel V, Dichtel-Danjoy M-L, Sagne C. et al. Biological functions of p 53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 2011; 18: 1815-1824 DOI: 10.1038/cdd.2011.120.
• 6 Leroy B, Ballinger ML, Baran-Marszak F. et al. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 2017; 77: 1250-1260 DOI: 10.1158/0008-5472.CAN-16-2179.
• 7 Gonzalez KD, Buzin CH, Noltner KA. et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 2009; 46: 689-693 DOI: 10.1136/jmg.2008.058958.
• 8 Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mirzaa G, Amemiya A. Hrsg. GeneReviews^® . Seattle (WA): University of Washington, Seattle; 1993. Accessed May 07 2021 at: http://www.ncbi.nlm.nih.gov/books/NBK1247/
• 9 Moog U, Felbor U, Has C. et al. Disorders Caused by Genetic Mosaicism. Dtsch Arztebl Int 2020; 116: 119-125 DOI: 10.3238/arztebl.2020.0119.
• 10 Renaux-Petel M, Charbonnier F, Théry J-C. et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet 2018; 55: 173-180 DOI: 10.1136/jmedgenet-2017-104976.
• 11 Weber-Lassalle K, Harter P, Hauke J. et al. Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial. Hum Mutat 2018; 39: 2040-2046 DOI: 10.1002/humu.23653.
• 12 Weitzel JN, Chao EC, Nehoray B. et al. Somatic TP53 variants frequently confound germ-line testing results. Genet Med 2018; 20: 809-816 DOI: 10.1038/gim.2017.196.
• 13 Coombs CC, Zehir A, Devlin SM. et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell 2017; 21: 374-382.e4 DOI: 10.1016/j.stem.2017.07.010.
• 14 Chen S, Liu Y. p 53 involvement in clonal hematopoiesis of indeterminate potential. Curr Opin Hematol 2019; 26: 235-240 DOI: 10.1097/MOH.0000000000000509.
• 15 Evans DG, Woodward ER, Bajalica-Lagercrantz S. et al. Germline TP53 Testing in Breast Cancers: Why, When and How?. Cancers 2020; 12: 3762 DOI: 10.3390/cancers12123762.
• 16 Richards S, Aziz N, Bale S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424 DOI: 10.1038/gim.2015.30.
• 17 Frebourg T, Bajalica Lagercrantz S, Oliveira C. et al. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet 2020; 28: 1379-1386 DOI: 10.1038/s41431-020-0638-4.
• 18 Villani A, Shore A, Wasserman JD. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 2016; 17: 1295-1305 DOI: 10.1016/S1470-2045(16)30249-2.
• 19 Kratz CP, Achatz MI, Brugières L. et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research 2017; 23: e38-e45 DOI: 10.1158/1078-0432.CCR-17-0408.
• 20 Schlegelberger B, Kreipe H, Lehmann U. et al. A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies. Pediatr Blood Cancer 2015; 62: 1481-1484 DOI: 10.1002/pbc.25486.
• 21 Li FP, Fraumeni JF, Mulvihill JJ. et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362
• 22 Chompret A, Abel A, Stoppa-Lyonnet D. et al. Sensitivity and predictive value of criteria for p 53 germline mutation screening. J Med Genet 2001; 38: 43-47 DOI: 10.1136/jmg.38.1.43.
• 23 Bougeard G, Sesboüé R, Baert-Desurmont S. et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45: 535-538 DOI: 10.1136/jmg.2008.057570.
• 24 Tinat J, Bougeard G, Baert-Desurmont S. et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009; 27: e108-e109 DOI: 10.1200/JCO.2009.22.7967. author reply e110